Eli Lilly and Company (NYSE:LLY) Stake Boosted by Waters Parkerson & CO. LLC

Waters Parkerson & CO. LLC grew its stake in shares of Eli Lilly and Company (NYSE:LLY – Get Rating) by 2.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,970 shares of the company’s stock after purchasing an additional 290 shares during the quarter. Waters Parkerson & CO. LLC’s holdings in Eli Lilly and were worth $3,547,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. FMR LLC boosted its position in shares of Eli Lilly and by 2.9% during the second quarter. FMR LLC now owns 32,439,666 shares of the company’s stock worth $10,517,913,000 after buying an additional 898,976 shares during the period. Jennison Associates LLC boosted its position in shares of Eli Lilly and by 31.1% during the second quarter. Jennison Associates LLC now owns 10,358,066 shares of the company’s stock worth $3,358,396,000 after buying an additional 2,456,760 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Eli Lilly and by 2.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 3,869,274 shares of the company’s stock worth $1,108,044,000 after buying an additional 83,299 shares during the period. Amundi boosted its position in shares of Eli Lilly and by 0.9% during the second quarter. Amundi now owns 3,766,227 shares of the company’s stock worth $1,230,725,000 after buying an additional 34,190 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its position in shares of Eli Lilly and by 54.8% during the first quarter. Arrowstreet Capital Limited Partnership now owns 3,311,713 shares of the company’s stock worth $948,375,000 after buying an additional 1,172,504 shares during the period. 82.13% of the stock is owned by institutional investors.

Insider Buying and Selling at Eli Lilly and

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 6,131 shares of the business’s stock in a transaction on Wednesday, November 2nd. The shares were sold at an average price of $362.07, for a total transaction of $2,219,851.17. Following the sale, the insider now directly owns 103,357,679 shares of the company’s stock, valued at approximately $37,422,714,835.53. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, major shareholder Lilly Endowment Inc sold 6,131 shares of the company’s stock in a transaction on Wednesday, November 2nd. The shares were sold at an average price of $362.07, for a total value of $2,219,851.17. Following the transaction, the insider now directly owns 103,357,679 shares of the company’s stock, valued at $37,422,714,835.53. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Acquisition Corp Kearny purchased 29,992,668 shares of the company’s stock in a transaction dated Wednesday, November 30th. The stock was bought at an average cost of $12.50 per share, for a total transaction of $374,908,350.00. Following the completion of the purchase, the insider now directly owns 100 shares of the company’s stock, valued at approximately $1,250. The disclosure for this purchase can be found here. Insiders have sold a total of 120,141 shares of company stock valued at $44,151,279 in the last three months. 0.12% of the stock is currently owned by company insiders.

Eli Lilly and Stock Down 0.1 %

NYSE:LLY traded down $0.50 during trading hours on Wednesday, hitting $345.89. 581,116 shares of the stock traded hands, compared to its average volume of 2,422,829. The firm has a 50 day moving average price of $361.80 and a 200 day moving average price of $338.46. The company has a current ratio of 1.13, a quick ratio of 0.88 and a debt-to-equity ratio of 1.39. Eli Lilly and Company has a fifty-two week low of $231.87 and a fifty-two week high of $384.44. The firm has a market cap of $328.66 billion, a price-to-earnings ratio of 52.01, a PEG ratio of 2.12 and a beta of 0.36.

Eli Lilly and (NYSE:LLY – Get Rating) last announced its earnings results on Tuesday, November 1st. The company reported $1.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.97 by $0.01. Eli Lilly and had a net margin of 20.63% and a return on equity of 80.80%. The company had revenue of $6.94 billion for the quarter, compared to the consensus estimate of $6.91 billion. Equities research analysts anticipate that Eli Lilly and Company will post 7.77 earnings per share for the current year.

Eli Lilly and Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 10th. Shareholders of record on Wednesday, February 15th will be paid a dividend of $1.13 per share. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.98. This represents a $4.52 annualized dividend and a yield of 1.31%. The ex-dividend date of this dividend is Tuesday, February 14th. Eli Lilly and’s payout ratio is 58.86%.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on LLY shares. Morgan Stanley reduced their price objective on Eli Lilly and from $446.00 to $440.00 and set an “overweight” rating for the company in a research report on Wednesday, December 14th. SVB Leerink upped their target price on Eli Lilly and from $384.00 to $410.00 and gave the stock an “outperform” rating in a research report on Friday, December 16th. Barclays upped their target price on Eli Lilly and from $395.00 to $400.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 3rd. Cowen upped their target price on Eli Lilly and from $390.00 to $430.00 and gave the stock an “outperform” rating in a research report on Monday, December 5th. Finally, UBS Group cut their target price on Eli Lilly and from $428.00 to $420.00 and set a “buy” rating for the company in a research report on Thursday, December 15th. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $384.11.

Eli Lilly and Company Profile

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.